Use of Most Bothersome Symptom as a Coprimary Endpoint in Migraine Clinical Trials: A Post‐Hoc Analysis of the Pivotal ZOTRIP Randomized, Controlled Trial

OBJECTIVE: To better understand the utility of using pain freedom and most bothersome headache‐associated symptom (MBS) freedom as co‐primary endpoints in clinical trials of acute migraine interventions. BACKGROUND: Adhesive dermally applied microarray (ADAM) is an investigational system for intracu...

Descripción completa

Detalles Bibliográficos
Autores principales: Dodick, David W., Tepper, Stewart J., Friedman, Deborah I., Gelfand, Amy A., Kellerman, Donald J., Schmidt, Peter C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Submissions
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174959/
https://www.ncbi.nlm.nih.gov/pubmed/29782049
http://dx.doi.org/10.1111/head.13327

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174959/
https://www.ncbi.nlm.nih.gov/pubmed/29782049
http://dx.doi.org/10.1111/head.13327

Ejemplares similares